Step aside, psilocybin: A new shroom is in town.

According to a new study by researchers at the University of California (UC) San Diego’s Herbert Wertheim School of Public Health and Human Longevity Science, the use of Amanita muscaria mushrooms has surged in the U.S. based upon Google searches.

The research indicates Google searches increased by 114 percent from 2022 to 2023, according to a study published June 10 in the American Journal of Preventive Medicine. The study was written by lead author Eric Leas, as well as Nora Satybaldiyeva, Wayne Kepner, Kevin H. Yang, Raquel M. Harati, Jamie Corroon, and Matthieu Rouffet, of UC San Diego.

Interest in the mushroom is growing each year. “Interest in psilocybin-containing mushrooms is increasing in the U.S., with 12.3% of U.S. adults reporting use of psilocybin-containing mushrooms in 2022, up significantly from 11.4% in 2021,” the study reads. “This makes psilocybin-containing mushrooms the most commonly used hallucinogenic substance. This growing interest in psilocybin-containing mushrooms has also sparked a new commercial market for other types of mushrooms.”

Like psilocybin mushrooms, which are not closely related, Amanita muscaria mushrooms, or Fly Agaric mushrooms, also have psychotropic effects: weightlessness, visual and auditory hypersensitivity, space distortion, unawareness of time, and hallucinations, however amanitas tend to be slightly more poisonous.

UC San Diego Today reports that the study shows people are taking more amanitas, perhaps without being equipped with the knowledge of doing so. Researchers noted, however, that mushrooms like psilocybin have a place in therapy, but that people should do so safely.

Since amanitas are legal in most states (not you, Louisiana), they’re becoming popular and researchers think it’s due to the rise in popularity of psilocybin.

“There is a lot of interest in the therapeutic potential for psilocybin and for good reason. But at the same time, a growing industry may be trying to capitalize on this interest by marketing other mushrooms. For example, some manufacturers are calling Amanita muscaria products ‘magic mushroom gummies’ and not disclosing what mushroom they contain, or not making it clear Amanita muscaria is a different mushroom than psilocybin and has essentially no clinical evidence supporting its use as a therapy,” said Eric Leas, Ph.D., M.P.H., assistant professor in the UC San Diego Herbert Wertheim School of Public Health and Human Longevity Science and senior author on the paper.

The psychotropic effects are produced by compounds, mostly muscimol and ibotenic acid, its biosynthetic precursor.

Researchers stressed that amanitas behave totally differently than psilocybin. Amanitas are a depressant, for instance.

“There may be some pharmaceutical potential to Amanita muscaria, but muscimol does not have the same effects on the body as psilocybin, so it probably would not have the same treatment applications if it ever went through drug development. For this reason, it is misleading not to clearly distinguish between muscimol and psilocybin. If someone is consenting to a psychedelic experience, they have a right to know what substance they are taking and receive accurate information about its potential health benefits and health risks.”

For the most part, what researchers are seeing is that safety protocols are mostly being ignored and the only thing you may find is a supplement-like list of ingredients. Researchers were unable to find any evidence that safety measures were taken.

“We have found that many manufacturers use supplement labeling, including ‘Supplement Facts’ panels,” said Leas. “However, there is a process for bringing a supplement to market that involves presenting safety data and filing an application, and we cannot find any evidence that any of these manufacturers have gone through this process, and this makes the current products sold in this manner illegal.”

Active compounds in amanitas are no toy, researchers said, and could affect certain people adversely.

“In my view, if a manufacturer wanted to develop a dietary supplement from Amanita muscaria, the application probably would not be approved because of muscimol and ibotenic acids’ inherent risks,” he added. “But right now it is the ‘Wild West,’ and companies are profiting from delayed enforcement while putting consumers at risk.” 

High Times has reported on the effects and history of amanitas several times before.

Beginning in the December, 1976 issue of High Times, writer Tom Robbins explored amanitas and the books that inform readers about them. Then again in the December, 1979 issue of High Times, writers examined the connections between Santa Claus and a specific kind of psychedelic mushroom known as the fly agaric, aka the toadstool that conquered the universe. In fact, the mythology behind Santa could be related to a shaman in Lapland who ate Amanita muscaria. 

Until more is known about amanitas, researchers urge caution for those exploring its active compounds.

The post Rise in Amanita Muscaria Shroom Use Worries Researchers first appeared on High Times.

The post Rise in Amanita Muscaria Shroom Use Worries Researchers appeared first on Paradise Found.

A new study examined the effects of psilocybin in an animal model for treating anorexia nervosa, showing that the compound improves body weight maintenance in female rats, facilitating what they call cognitive flexibility.

Anorexia nervosa (AN) is deadly—having one of the highest mortality rates of any known psychiatric disease. It killed people such as Karen Carpenter of The Carpenters, or a list of famous models who dealt with unrealistic body goals. It affects women more often but also 10-15% of people with AN are male.

The study, called “Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms,”  was led by Dr. Claire Foldi of the Monash University Biomedicine Discovery Institute and published recently in the journal Molecular Psychiatry.

People with eating disorders often suffer from symptoms like body dysmorphia and a poor self-image. These rigid thought patterns are difficult to overcome, and conventional medicine may not make much of a difference. Researchers observed a specific mechanism within the brain, allowing psilocybin to make “anorexic thinking” more pliable.

Meanwhile, serotonin reuptake inhibitors, aka antidepressants, are the leading treatment, however they are used off-label and don’t appear to improve clinical symptoms in underweight people with anorexia, Foldi said. “Cognitive inflexibility is a hallmark of the condition often arising before symptoms of anorexia nervosa are obvious, and persisting after weight recovery—making this symptom a primary target for therapeutic intervention,” Foldi told MSN News.

Researchers used young female rats in the study because they are particularly vulnerable to developing a particular ABA phenotype—a feature that is not fully understood but has been connected to the increased prevalence of AN in young women. 

To test the effects of psilocybin on cognitive flexibility, saline or 5-HTR antagonists were administered 30 minutes prior to either saline or psilocybin treatment, at the completion of a training session. The following day the reward contingencies of the nose-poke ports were reversed, and rats underwent more testing.

“Clinical trials evaluating the safety and efficacy of psilocybin in people with AN have been ongoing since 2019, with the first pilot study recently reporting that it improves eating disorder symptoms in some individuals, but not others. Psilocybin may have transdiagnostic efficacy through several mechanisms relevant to the pathology of AN, including actions on the serotonergic system and cognitive flexibility. However, the details of how such mechanisms are altered by psilocybin in the context of AN remains unknown. 

The ABA paradigm, as they call it, involves unlimited access to a running wheel and time-restricted food access. At seven weeks of age, rats were individually housed in transparent living chambers with a removable food basket and a running wheel. They were given access to the wheel for seven days to determine baseline running wheel activity (RWA). The following day, psilocybin or saline was administered, wheels were locked for five hours and then it was reopened. Running activity was recorded electronically.

“Here, we show that psilocybin improves body weight maintenance in the ABA rat model and enhances cognitive flexibility in a reversal learning task by both reducing perseverative responding and promoting task engagement when reward contingencies are initially reversed. That psilocybin did not elicit changes in motivated responding (PR) or response suppression (extinction) following the same training and drug administration protocol suggests a selective improvement in adaptive cognition in the face of changing rules.”

Other Studies Show Psilocybin May Be Effective for Eating Disorders

Other studies linked psilocybin with eating disorders (EDs) like anorexia. Recently researchers Elena Koning and Elisa Brietzke explored the ways psilocybin can treat ED by its therapeutic benefits—also in combating rigid thought patterns. Koning, who is a doctoral student, recently wrote about her discoveries for PsyPost, explaining the reasoning behind her research.

Koning mentioned that in the age of social media, EDs are becoming increasingly troublesome, and that new approaches to those types of disorders are needed.

An earlier study, “Psilocybin-Assisted Psychotherapy as a Potential Treatment for Eating Disorders: a Narrative Review of Preliminary Evidence,” was published online ahead of print for Trends Psychiatry.

“Eating disorders (ED) are a group of potentially severe mental disorders characterized by abnormal energy balance, cognitive dysfunction and emotional distress,” researchers wrote. “Cognitive inflexibility is a major challenge to successful ED treatment and dysregulated serotonergic function has been implicated in this symptomatic dimension. Moreover, there are few effective treatment options and long-term remission of ED symptoms is difficult to achieve. There is emerging evidence for the use of psychedelic-assisted psychotherapy for a range of mental disorders. Psilocybin is a serotonergic psychedelic which has demonstrated therapeutic benefit to a variety of psychiatric illnesses characterized by rigid thought patterns and treatment resistance.”

The new study show’s psilocybin’s potential in the treatment of anorexia and other EDs.

The post Study Explores Psilocybin for Anorexia, Rigid Thought Patterns first appeared on High Times.

The post Study Explores Psilocybin for Anorexia, Rigid Thought Patterns appeared first on Paradise Found.

Recently, researchers Christopher P. Holstege and Rita Farah unveiled the results of their study on the increase in poison center calls for mushroom consumption. In “Psilocybin Exposures Reported to U.S. Poison Centers: National Trends Over a Decade,” the researchers explored the rising trend of accidental exposure to psilocybin between January 1, 2024-December 31, 2022. Holstege is a Professor of Emergency Medicine and Pediatrics and Farah is a Researcher of Epidemiology, both of which work at the University of Virginia.

Over a 10-year period, there were 4,055 exposure incidents recorded by the National Poison Data System, and 2,667 (65.8%) of those incidents involved adolescents or young adults between 13-25. From this number of people, 1,176 (75.3%) were adolescents, and 797 (72.1%) were young adults. One of researchers’ noteworthy observations was that cases didn’t rise between 2013-2018, but increased after 2019, and tripled in 2022.

Holstege and Farah co-wrote an analysis of their research, which was originally published in The Conversation.

Researchers noted that in May 2019, Denver, Colorado became the first city to decriminalize psilocybin, which was followed shortly after by Oakland, California, in June 2019. This trend continued with various other cities across the U.S., with Santa Cruz, California, in January 2020, Washington D.C. in November 2020, Sommerville, Massachusetts in January 2021, Seattle, Washington in October 2021, and Detroit, Michigan in November 2021. Additionally, Oregon was the first state to decriminalize psilocybin and introduce a legal therapy treatment program in November 2020. This was followed by the state of Colorado in November 2022.

Farah is an epidemiologist, and both of them worked together to identify potential harms. “Part of our job is to track public health risks related to poisons and to create efforts to prevent them,” the researchers wrote. “We are both concerned about the increase in calls to poison control centers related to psilocybin.”

However, the information collected by the National Poison Data System covers calls from across the country, making it impossible to know where exactly the poison calls came from.

The data shows that a majority of the reported calls between both adolescents and young adults resulted in the need for medical attention at a hospital or treatment facility. A majority of these cases included people who were experiencing “hallucinations, delusions, agitation, rapid heart rate, and confusion.”

Holstege and Farah expressed their overall concern for youth based on their observations. “Our findings correspond with a review of more than 30 studies that demonstrates a similar rise in acute cannabis poisoning among children and adolescents beginning after marijuana was legalized in 1996,” the researchers concluded. “We find this particularly alarming, since the states that legalized and cities that decriminalized psilocybin don’t allow anyone under 21 to use it or buy it. This suggests young people are getting it illegally.”

A study recently published in the Drug and Alcohol Dependence journal shows that there has also been an increase in law enforcement seizures of psilocybin over the past few years as well. “We found that the number of shroom seizures and the total weight of shrooms seized annually increased through 2022, and the greatest weight of shrooms seized was in the West,” said study co-author Joseph J. Palamar told High Times. Out of 4,526 seizure reports between 2017-2022, the numbers increased from 402 in 2017, to 1,396 in 2022.

While it’s clear that illegal mushroom cultivation and sales needs to be reduced in order to reduce access for adolescents and young adults, the legal psilocybin industry is struggling. Oregon’s psilocybin therapy treatment service program just passed its one-year mark, but has encountered challenges such as limited customers, partially due to high prices and advertising restrictions. Less than a year into its business, one psilocybin treatment center called The Journey has already closed up shop.

Across the U.S., researchers continue to study psilocybin to determine its effectiveness as a treatment for many medical conditions. One study that was published in Clinical Case Reports earlier in June showed that both psilocybin and MDMA can be beneficial in treating symptoms of long-COVID, also called longhauler’s. Sufferers of this condition usually experience anxiety, depression, headaches, and struggles with cognition.

Also in June, University of California, Berkeley announced that it will be embarking on a study to observe how psilocybin affects human perception. It’s the first psilocybin study that UC Berkeley is conducting using human subjects. “We have this incredible opportunity to characterize the psychedelic experience in real time—while it’s happening—using modern neuroimaging methods,” said UC Berkeley Center for the Science of Psychedelics director, Michael Silver. “Understanding the actions of psychedelics at a neuroscientific level will generate insights into how they’re working as medicines and will hopefully help us develop more effective treatments for mental health disorders. It will also shed light on some of the fundamental mysteries of the human brain, mind and consciousness and how they relate to each other.”

The post Poison Control Center Calls Increased Following Psilocybin Decriminalization first appeared on High Times.

The post Poison Control Center Calls Increased Following Psilocybin Decriminalization appeared first on Paradise Found.

It’s been over one year since Oregon’s first psilocybin therapy license was approved, and updated news reports are sharing that there aren’t enough customers to go around.

Vital Reset, owned by Heidi Venture, told the Oregon Capital Chronicle that it’s just a matter of time for people to become aware of the opportunity. “We think everybody knows that psychedelics can help them because we’re in this little bubble. But 99% of people have no idea what they could get out of a journey,” Venture said.

The Psilocybin Assisted Therapy Association hosted a one-day conference in May, called “Collaborence,” which was held in Portland, Oregon. Venture, along with more than 100 local psilocybin business owners, gathered together to attend panel discussions on the topic of the mental health crisis both in Oregon and throughout the country. Panelists also spoke about the current issues of their businesses, but also the benefits that they saw their patients.

Voters passed Measure 109 in November 2020, making Oregon the first state to legalize licensed psilocybin treatment centers. The first license was approved in May 2023 for EPIC Healing Eugene, which opened just a month later in June 2023. As of last September, there were 10 licensed service centers (not all of which were operational at the time, as well as four growers, and two lab testing facilities.

Between June 2023-December 2023, an estimated 700 people had taken part in an experience at a psilocybin treatment center. Between June 2023-June 2024, approximately 3,500 people have taken part in a psilocybin therapy session throughout the state’s 25 licensed centers. According to the Healing Advocacy Fund, a nonprofit organization that prioritizes safe and affordable psilocybin access, projects that the number of people who will take part in psilocybin therapy will increase to 7,000 by the end of 2024.

However, in March 2024, one licensed center called The Journey was already forced to shut down due to lack of customers. “I’ve absolutely loved doing this,” said founder Jenna Kluwe. “The numbers just weren’t where they needed to be.”

Commenting on the recent closure, Satori Farms PDX owner Tori Armbrust explained her concern for the Oregon psilocybin industry. “Unfortunately we’ve seen one service center close down. I imagine there will be more, because very quickly it’s going to get over-saturated,” Armbrust said, adding that competition will increase in 2025 when out-of-state businesses will be allowed to open psilocybin therapy centers in Oregon. “Overall, marketing seems to be a big challenge. But places are doing well, and there’s product going out to a lot of people,” Armbrust said.

Chariot owner Courtney Campbell said that her business isn’t profiting, but a reliable number of customers are keeping them in business. 

The Entheogen Institute, which trains students to be licensed facilitators, graduated about 70 people within the last year. However, institute owner Coeli Dwivedi told the Oregon Capital Chronicle that she has only had one paycheck. “I’m looking forward to having a real salary as well,” Dwivedi said.

Many therapy center operators are trying to bring in new customers through discounts, but are limited by rules that prevent psilocybin services from being advertised online. Oregon state law requires that a licensee can’t advertise through TV, radio, billboards, print media, or internet unless they can prove that the ads won’t reach more than 30% of an audience that is under 21. Due to these restrictions, psilocybin centers are primarily focusing on word of mouth and open houses to allow curious customers to learn more.

Facilitators are also running into problems where there aren’t enough openings to allow all of them to work. Currently, there are 325 licensed facilitators in Oregon, but some are finding their own clients and conducting facilitation illegally in homes or in Airbnb rentals. Facilitator Marlin Hofer said that he carries business cards around wherever he goes to promote the opportunity.

Another facilitator, Matthew Wissler, added that he would make his services free for low-income people in need, but Oregon’s law mainly attracts tourists or out-of-state or out-of-country patients instead.

Many service center operators are just pushing through the challenges in hopes that the future will bring more success. “If we just hang in there, stay positive, it will evolve into something we can all be proud of,” said Brain Brew PDX owner Mary Nielsen.

Recently, Gov. Tina Kotek signed Senate Bill 303 into law, which requires psilocybin service centers to collect and submit data to the Oregon Health Authority (OHA). The law is expected to take effect sometime in 2025 in an attempt to collect information about exact numbers of clients served, numbers of those who refused service, total numbers of adverse or severe reactions, and dosing averages, according to an Oregon Public Broadcasting report. “It’s important to remember that our administrative rules are a minimal requirement, and they’re not the best practices,” said OHA Psilocybin Services head Angela Allbee. “They’re there to create guidelines and protect public health and safety, and protect equity and access. It’s up to licensees to create best practices and inform us, so we can evaluate every year.”

The post A One-Year Update on Oregon’s Legal Psilocybin Program first appeared on High Times.

The post A One-Year Update on Oregon’s Legal Psilocybin Program appeared first on Paradise Found.

University of California, Berkeley (UC Berkeley) will observe human subjects in a study to determine if psilocybin, the active compound in magic mushrooms.The study marks UC Berkeley’s first study involving human subjects with a Schedule I substance—drugs with no currently accepted medical value. 

The study will examine how psilocybin changes the way our brain interprets information that we see and pushes us out of our normal state of mind. The UC Berkeley Center for the Science of Psychedelics (BCSP) is launching a new study designed to reveal the mechanisms behind how psychedelics shape human perception. 

In the experiment, healthy human participants will ingest psilocybin, a compound found in psychedelic mushrooms. All the while, researchers will observe how their brains light up. Each participant will then perform simple perceptual tasks while their visual cortex is monitored using functional Magnetic Resonance Imaging (fMRI). 

“We have this incredible opportunity to characterize the psychedelic experience in real time—while it’s happening—using modern neuroimaging methods,” Michael Silver, director of the BCSP and the study’s leader, told Berkeley News. “Understanding the actions of psychedelics at a neuroscientific level will generate insights into how they’re working as medicines and will hopefully help us develop more effective treatments for mental health disorders. It will also shed light on some of the fundamental mysteries of the human brain, mind and consciousness and how they relate to each other.”

Before this study, UC Berkeley researchers had to rely on animal subjects, typically mouse models, in order to study psilocybin as a Schedule I substance. Going beyond that usually requires DEA approvals.

For the BCSP, they had to work for years to acquire federal, state, and campus-level regulatory approvals in order to use psilocybin, and they must follow stringent rules for handling of it.

How Psilocybin Shapes the Way We Perceive Visual Information

Silver explained to Berkeley News in detail what excites him about the way psilocybin changes the way we see and process visual information.

Silver explained that our retina pick up about as much info and/or resolution as a 2007 camera—but our brains fill in the blanks, providing rich detail. “The way that we perceive the world is very unlike a video camera,” Silver said. “While a camera just passively records whatever comes through the lens, our brain takes that sensory information from the eyes and combines it with previous experiences to generate our conscious experience of the world. We make implicit assumptions—for example, that objects that are in one place tend to stay in one place, or that objects that are moving tend to continue moving along that trajectory—to help construct our perceptions.”

“Our area of interest is the visual system in the brain,” Silver told CBS News. “Psychedelics are a wonderful tool for understanding this.”

UC Berkeley’s Center for the Science of Psychedelics is underway and staff are recruiting volunteers, center director and UC Berkeley professor Michael Silver said.

“My love is science, not the administrative part of it,” Silver said. “I understand the importance of that, but the reason I am personally motivated to do this is to learn about the brain and to learn about the visual system and how we create conscious experience.”

“Visual priors” help define how our brain interprets information we see. In the new experiment supported by the BCSP, researchers will observe how psilocybin impacts visual perception and how these perceptions are generated in the brain. They plan to test a hypothesis known as REBUS, or relaxed beliefs under psychedelics, which proposes that psychedelics work by “relaxing” assumptions, so that our perceptions are shaped less by visual priors and more by raw sensory information. 

Psychedelic-assisted therapy is gaining traction because of the ability of psychedelics to push people out of mental patterns.

“If you think about the disorders where we have the best evidence that psychedelics can be a useful therapy, including PTSD, depression, anxiety and various substance use disorders, they often involve a maladaptive prior or belief, such as a negative self-image,” Silver said. “The REBUS theory proposes that psychedelic-assisted therapy works by reducing the influence of these priors, followed by construction of healthier priors through psychotherapy.”

The team hopes that the information they glean will help to better understand how our minds perceive information and how psilocybin impacts those abilities.

“We know a great deal about the different structures and neural types in the visual system, and as a result, we have some understanding of what visual priors and sensory information look like in the brain, and how they interact with each other,” Silver said. “And so, using functional magnetic resonance imaging, we can test this theory in a very rigorous way.”

The post UC Berkeley To Enlist Human Subjects in Groundbreaking Psilocybin Study first appeared on High Times.

The post UC Berkeley To Enlist Human Subjects in Groundbreaking Psilocybin Study appeared first on Paradise Found.

A psilocybin treatment bill was recently introduced on June 6 by California Sen. Brian W. Jones and Sen. Josh Becker, which if passed would create a pilot program for psilocybin therapy.

Senate Bill 803, also called the Heal Our Heroes Act, was attached as an amendment to an unrelated bill last week. If passed, it would allow San Francisco County, Santa Cruz County, and San Diego County to conduct a pilot program for veterans and first responders to use psilocybin or psilocyn. Those counties would be in charge of approving various facilitators, including “licensed physician or surgeon, clinical psychologist, licensed clinical social worker, nurse practitioner, physician assistant, licensed professional clinical counselor, or a naturopathic doctor.” The program would last for three years, with data set to be compiled and reported starting after the beginning of the second year.

In a press release that introduces the bill on June 6, Jones stressed the importance of providing the opportunity for veterans to benefit from psilocybin treatments. “As a dedicated advocate for veterans and first responders, I firmly believe it is our duty to support and heal the brave individuals who served our country and communities,” Jones said. “To be clear, I’m not calling for the widespread legalization of psychedelic drugs. Rather, I’m championing a targeted medical treatment aimed specifically at aiding veterans and first responders in their recovery. The Heal Our Heroes Act is a thoughtful and balanced measure designed to rigorously study the effectiveness of these treatments with the hope of providing much-needed relief to those patients who need it most.”  

Becker followed up with high expectations to support veterans and first responders. “SB 803 is an entirely new and innovative effort that is the result of comprehensive discussions on how the state can best support our veterans and first responders with a viable treatment for work-induced post-traumatic stress disorder,” Becker said. “We have a responsibility to do everything possible to provide quality care to these heroes, and I am proud to joint author this bipartisan effort that will have a real impact on the people who serve our state and country.”

The Heal Our Heroes Act is sponsored by two veterans organizations: the Heroic Hearts Project and Veterans Exploring Treatment Solutions (VETS). A representative from the Heroic Hearts Project, Jason Moore Brown, is also a sponsor of the measure. In a press statement, he explained that he has personally struggled with PTSD and mental health as a decorated combat veteran, and approved of Jones and Becker’s bill. “We have lost over 130,000 Veterans to suicide since the Global War on Terror began in 2001,” Moore said. “I know first hand that psilocybin, when used responsibly and with support, has the potential to save the lives of California’s Veterans. This pilot program is the responsible first step to reducing, and hopefully ending, the Veteran suicide epidemic.”

In fall 2023, the legislature passed Senate Bill 58 (sponsored by Sen. Scott Wiener and Assemblymember Marie Waldron) but was vetoed by California Gov. Gavin Newsom. “Both peer-reviewed science and powerful personal anecdotes lead me to support new opportunities to address mental health through psychedelic medicines like those addressed in this bill,” Newsom said. “Psychedelics have proven to relieve people suffering from certain conditions such as depression, PTSD, traumatic brain injury, and other addictive personality traits. This is an exciting frontier and California will be on the front-end of leading it. . . . I urge the legislature to send me legislation next year that includes therapeutic guidelines.”

Recently in May, a different psychedelic bill that also sought to pass treatment centers recently ended its run in the Senate Appropriations Committee. Called the “Regulated Therapeutic Access to Psychedelics Act,” Senate Bill 1012 would have created dedicated psychedelic service centers to allow patients legal access to psilocybin, DMT, mescaline, and MDMA in a regulated setting. SB-1012, also sponsored by Weiner, described the bill as a “direct response to the Governor’s request” in April.

Following the rejection of SB-1012 in May, numerous advocate organizations condemned the decision to terminate the bill. “We are deeply disappointed that the Legislature has missed this opportunity after four years of debate to enact a policy that would create a responsible program and promote the safer use of psychedelics in California and create a model policy for the rest of the country,” said Alliance for Safer Use of Psychedelics (ASUP) campaign director Jared Moffat. “Californians will continue to seek out psychedelics for all sorts of reasons, including to help alleviate mental health challenges like PTSD, depression and anxiety. Many will do so without guided support and use psychedelics on their own, which increases risks. Veterans and others will continue to leave the country or go underground to seek unregulated services that may be unsafe.”

These bills failed to pass, but advocates are pushing for a potential ballot initiative in 2026 that would legalize psychedelic substances such as psilocybin and MDMA. After Weiner’s bill was killed, he told KQED that he will keep trying to push for access to psychedelics. “We are not giving up, whether that means introducing a new bill or ballot measure, this issue is not going away,” he said. “We know these substances are helping people turn their lives around.”

The post Psilocybin Therapy Pilot Program Bill Introduced in California first appeared on High Times.

The post Psilocybin Therapy Pilot Program Bill Introduced in California appeared first on Paradise Found.

Two new exhibits recently opened up in Denver, Colorado exploring themes surrounding magic mushrooms and cannabis.

The first exhibit is “Mycolandia,” which opened at the Dateline Gallery in Denver, Colorado on June 7 and will remain open through June 23. “MYCOLANDIA celebrates Mycology in general exploring the evolution of edible fungi and its symbiotic relationship with humanity. In otherwords, It’s a show about mushrooms. ,” the gallery said on social media.

The show features works from 13 different artists, such as Noah Travis Phillips. According to an interview with Westword, Phillips explained his thought process behind the theme. “I definitely thought of the diverse array of mushrooms,” Phillips said. “All the ways fungus and mushrooms exist in the world, the different ways that humans interface with them—whether as food, or an intoxicating substance, or all of the bio remediation people are doing with mushrooms.”

Attendees can view Phillips’ unique Generative Adversarial Network (GAN) AI images that he developed to represent mushrooms’ inherent psychedelic properties. “It’s much more colorful. They’re all rainbowy. They’re kind of melting. They’re kind of bulbous,” said Phillips. “I think they suggest interesting things about mushroom root networks—those mycorrhizae. Some of them look like they have spores drifting from them.”

He added that he’s been an artist for 25 years, and has spent about six years working with GAN. “My relationship to the GANs is like a poetic visual synthesizer for producing improvisatory material to collage with,” he explains. “I’m engaging in a dialogue with that kind of cutting edge of technology and seeing what its creative potential is.”

Phillips also cut out 45 images which are situated close to the floor, which forces viewers to look downward. “To me, setting them up that way makes it more reminiscent of mushroom foraging, or mushroom hunting, where people have to get low to go find them,” Phillips explained.

The second exhibit is inspired by the “Science-Informed Art Model,” called “Grow Up,” also debuted on June 7 and will stay open through July 7. The art show “empowers young student classes from various Denver institutions to explore the effects of high-concentration cannabis through their own creative lens,” according to a press release. Teachers were chosen from four middle and high schools in Colorado, who then attended workshops presented by scientists and researchers at the University of Colorado School of Public Health. Then those teachers developed workshops for their students who created their own art inspired by “high-concentration cannabis.”

The result is a varied selection of abstract art where students transformed scientific data into their own concepts. “The beautiful part about bringing science and art together is [figuring out] how we interpret information and communicate it with a community in ways that are much more relatable or understandable, or challenge people to question what they’re observing,” said PlatteForum Program Director Alejandra Calvo.

Shaunie Berry, the curator for “Grow Up,” explained that this exhibit was an opportunity to promote healthy decision making. We really created a space in which they could be open and vulnerable,” said Berry. “We were just giving them a lot of information about the mental health aspect of it because they are young and their brains aren’t fully formed yet; their decision-making skills aren’t completely formed yet.”

Both Calvo and Berry worked together to help students better comprehend cannabis and its effects from an artistic point of view. “I think kids just are naturally more creative,” said Berry. “The older you get, it becomes a little more stifled. And you have to pull more strings to get them to do it.”

Meanwhile the state’s cannabis industry is making new discoveries about its products. A recent study released in March shows that 70% of THC potency levels on cannabis products in Colorado are at least 15% higher than lab tests show. “Among the 23 flower samples analyzed, 18 displayed lower THC levels than reported—with 16 falling below 15% of the stated value, 13 falling below 30% of the reported THC and three samples falling below half of the reported THC,” said a report written by University of Colorado Boulder professor Anna Schwabe. “THC levels averaged 9.75% back in 2009, based on testing of DEA-seized cannabis flower. Today, levels reportedly surpass 35%, though they’re not as common as consumers have been led to believe,” Schwabe continued.

The Colorado cannabis industry is saturated with cannabis products and has seen a steady decline in sales recently. According to a report from Politico, Colorado cannabis sales reached a peak of $2.2 billion in 2020. Since legalization began in 2014, the state has generated more than $15 billion in total sales as well. However, data from 2022 shows that the state’s cannabis revenue decreased significantly ($1.7 billion), which also continued into 2023 ($1.5 billion).

Recent legislation in Colorado has targeted positive praise of drugs on social media. While the Senate approved the bill in April, SB24-158 was sent to the House in May and has not received any further discussion. If passed, it would prevent language on social media that pertains to any black market or illicit drugs, although cannabis would technically be a safe topic if mentioned in a legal capacity.

The post Two Exhibits in Colorado Feature Art Inspired by Mushrooms, Cannabis first appeared on High Times.

The post Two Exhibits in Colorado Feature Art Inspired by Mushrooms, Cannabis appeared first on Paradise Found.

A 41-year-old woman in a case study reported remarkable improvements of longhauler’s symptoms after taking psilocybin and MDMA-assisted therapy sessions.

A case report, “Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report,” was published May 24 in the journal Clinical Case Reports. The woman in the case study was healthy before contracting COVID-19 in February 2022, and she was vaccinated three times. She reported symptoms of long COVID or longhauler’s: severe anxiety, depression, debilitating headaches, and cognitive difficulties.

The woman tried many methods to get relief from the disease: fasting, massage therapy, acupuncture, and meditation. The woman resorted to psilocybin and bought golden teacher shroom spores online and consumed significant improvement of the symptoms in subsequent tripping sessions.

“The patient’s first dosing session was on May 5, 2022, where she consumed 1 g of dried whole golden teacher psilocybin cubensis mushrooms from an online store,” the report reads. “The patient subjectively reported a 20% improvement in her depression, fatigue, joint pains, and headache for seven days. However, she also reported chills and shivering with a sensation of being cold while ‘coming up.’”

About a month later, she ingested 125 mg of MDMA, followed by two separate doses of psilocybin. After this session, she said her symptoms improved significantly—80% percent overall—and that she was able to resume her PhD studies.

“The patient’s second dosing session was 24 days later on May 29th where she consumed a single dose of MDMA 125 mg, 1 h later 2 g of whole dried golden teacher psilocybin cubensis mushrooms prepared in a tea, and 1 hour later a second dose of 2 grams of whole dried golden teacher psilocybin cubensis mushrooms prepared in a tea.”

Another month later she ate more shrooms and she saw huge improvements again.

“Six weeks later (on July 16th), her head pressure returned at approximately 30% of its previous severity,” the report reads. “After another 2 g dose of psilocybin cubensis mushrooms, her symptoms abated to 90% relief of symptoms. She was able to work part-time thereafter and return full-time in September.”

“After several months of improvement, the patient reported experiencing an early November relapse of her post-COVID-19 symptoms in the setting of a non-COVID-19 flu-like illness. Her headache returned, although it was less severe and not as frequent as before. The patient decided to try another dosing session with psychedelics on November 24th. This time, 2 g of dried golden teacher psilocybin cubensis mushrooms led to a remission of her symptoms. The patient subjectively reported complete resolution of her symptoms. The patient was again able to return to work 3 days later and continue with her PhD studies.”

Research on larger groups of people is needed in order to determine why psychedelics seem to improve long-COVID symptoms.

Science Reports noted that researchers at Columbia University have launched a small pilot trial to explore whether single-dose hallucinogenic treatments can really relieve long COVID symptoms.

Other Studies Show Potential for Cannabis in COVID Treatment

Beyond psychedelics, cannabis—itself a minor psychedelic—has also been linked to COVID improvements. Cannabis consumers with COVID-19 experienced “better outcomes and mortality” compared to similar patients who did not use cannabis, in a recent study.

The study, entitled “Exploring the Relationship Between Marijuana Smoking and Covid-19,” was announced at a meeting for the American College of Chest Physicians, which was held in Honolulu, Hawaii on Oct. 11. It was also published in the October issue of CHEST Journal.

Researchers noted that they analyzed data from the National Inpatient Sample, which is the largest publicly available collection of inpatient healthcare data—recording about seven million hospital visits per year. Researchers studied 322,214 patients over 18 years of age, with only 2,603 stating that they were cannabis consumers.

Each cannabis-consuming patient was matched 1:1 with a non-consumer, as well as their “age, race, gender, and 17 other comorbidities including chronic lung disease.” The other comorbidities included obstructive sleep apnea, obesity, hypertension, and diabetes mellitus, which were more commonly found in non-users.

In these comparisons, cannabis users experienced a lowered rate of specific conditions. “On univariate analysis, marijuana users had significantly lower rates of intubation (6.8% vs 12%), acute respiratory distress syndrome (ARDS) (2.1% vs 6%), acute respiratory failure (25% vs 52.9%) and severe sepsis with multiorgan failure (5.8% vs 12%),” researchers explained. “They also had lower in-hospital cardiac arrest (1.2% vs 2.7%) and mortality (2.9% vs 13.5%).”

“Marijuana smokers had better outcomes and mortality compared to non-users,” researchers concluded. “The beneficial effect of marijuana use may be attributed to its potential to inhibit viral entry into cells and prevent the release of proinflammatory cytokines, thus mitigating cytokine release syndrome.”

The growing amount of evidence shows that psychedelics and cannabis may be the key to solving the riddle of COVID and long-COVID symptoms.

The post COVID Long-Hauler’s Symptoms Significantly Improved with Psilocybin, MDMA first appeared on High Times.

The post COVID Long-Hauler’s Symptoms Significantly Improved with Psilocybin, MDMA appeared first on Paradise Found.

A newly published study from researchers at New York University found that individuals dealing with a stutter derived some benefit from substances such as psilocybin, the psychoactive compound in “magic mushrooms,” and LSD.

“Given the positive effects of psychedelics on conditions like anxiety and PTSD, which share symptoms with stuttering, we think that investigating the potential impact of psychedelics on stuttering can be a fruitful area of research,” said Eric S. Jackson, an associate professor of communicative sciences and disorders at NYU Steinhardt School of Culture, Education, and Human Development, and the lead author of the study. 

The research, published this month in the Journal of Fluency Disorders, is the “first study to explore self-reported experiences of self-identified stutterers using classic psychedelics.”

“Stuttering poses challenges to social, occupational, and educational aspects of life. Traditional behavioral therapies can be helpful but effects are often limited. Pharmaceutical treatments have been explored, but there are no FDA-approved treatments for stuttering. Interest has grown in the potential use of classic psychedelics, including psilocybin and LSD, which have shown effectiveness in treating disorders with similar symptoms (e.g., anxiety, depression, PTSD). The potential effects of psychedelics on stuttering have not been explored,” Jackson and his team wrote in the study’s abstract.

Stuttering is “typically characterized by its symptoms—intermittent disruptions in speech,” they added. 

“Stuttering, or the possibility of stuttering, also triggers anxiety, fear, and shame which significantly impact quality of life. Negative reactions of listeners, such as teasing or mocking exacerbate these feelings, complicating the individual’s ability to cope with and move forward in speech when stuttering occurs. The speech of stutterers is amenable to change in therapy, but such change is often not durable with relics of tension, struggle, and avoidance re-emerging,” the researchers said. “To achieve lasting changes, stutterers may benefit from redefining their relationship with stuttering, exploring concepts like openness and self-acceptance. There is a pressing need for innovative approaches that support overall well-being, reduce negative thoughts and emotions, and enhance ease of communication for stutterers.”

They “conducted a preliminary investigation of self-identified stutterers who report their experiences taking classic psychedelics on the online messaging forum, Reddit,” before performing a qualitative analysis on “114 publicly available posts, extracting meaningful units and assigning descriptor codes inductively.”

The researchers said that their search of Reddit “yielded 167 posts, with 14 excluded for lacking firsthand accounts (e.g., describing others’ experiences) and 39 for not discussing classic psychedelics (rather, they discussed ketamine or MDMA). 

“The final sample comprised 114 posts from 104 Reddit distinct users, including multiple contributions from some users. Due to 12 users deleting their usernames, the exact number of unique users was estimated to be at least 92. Results reflective of individual percentages were based on 104,” they explained.

“We then deductively organized responses into an established framework of psychedelics which includes behavioral, emotional, cognitive, beliefbased, and social effects. These effects were subsequently grouped under organizing themes (positive, negative, neutral),” they wrote.

A majority of the users –– 74 percent –– ”reported positive overall short-term effects particularly related to behavioral and emotional change (e.g., reduced stuttering and anxiety), but negative (9.6%), mixed (positive and negative; 4.8%), and neutral overall experiences (11.6%) were also reported.” 

“The results support the possibility that psychedelics my impact stuttering, but caution must be applied in their interpretation given the entirely uncontrolled research setting and potential adverse health effects of psychedelics as reported elsewhere. While these results do not encourage the use of psychedelics by stutterers, they suggest that future work could examine the impact of psychedelics on stuttering under supervised and in clinically controlled settings,” the researchers wrote. 

They explained that the “results from a qualitative analysis of self-identified stutterers’ experiences of classic psychedelics, providing an initial investigation of the potential impact of psychedelics on stuttering from the perspective of stutterers.” 

The most reported effect among Reddit users, the researchers said, “was reduced stuttering, with half of users reporting a reduction in their stuttering.” 

“Users also reported reduced effort, ‘improved’ speech, and increased speech control while on psychedelics or shortly thereafter,” the researchers said. 

“People who stutter are in need of more effective treatments to manage intermittent disruptions in speech communication and also provide relief from distress that accompanies their social experiences, such as anxiety, depression, and suicidal ideation,” they wrote in their conclusion. “To date, there are no FDA-approved pharmacotherapies to treat stuttering. Our study suggests that some users on the internet forum Reddit who self-identify as people who stutter have reported beneficial short-term outcomes.”

Jackson said that the “results support the possibility that psychedelics may impact stuttering, but caution must be applied in their interpretation given the entirely uncontrolled research setting and potential adverse health effects of psychedelics as reported elsewhere.” 

“While these results do not encourage the use of psychedelics by stutterers, they suggest that future work could examine the impact of psychedelics on stuttering in randomized controlled clinical trials,” Jackson said. 

The post Study: Psychedelics May Help Stuttering first appeared on High Times.

The post Study: Psychedelics May Help Stuttering appeared first on Paradise Found.

A pilot program on the benefits of synthetic psilocybin for mental health issues like post-traumatic stress disorder (PTSD) is set to begin this summer at Yale University in New Haven, Connecticut. 

A study cohort will consist of 50 patients, mostly veterans and first responders, who are with mental health concerns like depression and addiction. Participants will take 25 mg of synthetic psilocybin, and after the psychedelic effects wind down, they will discuss issues and progress (or lack thereof) with trained therapists.

Connecticut Post reports that the goal is to fulfill the need for state data that has been lacking, according to state Rep. Michelle Cook (D-Torrington).

“We need to have the data to show that there is documented proof of what that therapy does,” Cook said. “We know that it has some incredible outcomes when it is done right, when it’s done by people that are trained in how to use it for treatment of PTSD and so forth.”

Researchers at Yale have been studying the “psychological, neurobiological, and therapeutic effects of psychedelic substances” like psilocybin for decades..

Using a Schedule 1 drug in a clinical setting creates a set of unique problems, including the inability to use insurance. “Even though it’s a research program, you are treating them clinically. And then, in order to treat them clinically, you need to have malpractice coverage,” said Yale researcher Ben Kelmendi. Kelmendi and his team are about to embark on a first-of-its-kind study, a pilot program at Yale.

Research on the medical benefits of  psilocybin have been severely hampered due to legal restrictions, Kelmendi said. Only certain qualifying conditions are acceptable in this case. PTSD, for instance, is a complex issue that many people fail to treat.

“With veterans, they will not seek treatment right away,” Kelmendi said. “They will start turning to alcohol or other substances, and so that now they have a comorbidity, and that comorbidity—which really is their own way of coping—will exclude them from the study. They are real patients who are actually suffering and who actually need help. They cannot access these medicines because they do not fit that cookie-cutter profile.” 

The impact of PTSD is hard to define as it affects multiple aspects of daily life.

“There is no one scale that actually captures the complexity of one’s daily functional impairment. It’s actually an index of several different scales,” he said. “One is days missed at work, productivity and relationships, just more daily living. I think that is much more important than saying ‘Oh, have your PTSD symptoms improved or not?’”

Participants will take 25 mg of synthetic psilocybin, enough to induce a psychedelic experience, and the therapy is patient-directed. They will be taken in a comfortable space and about six hours later, participants will undergo a psychotherapy session. 

“Twenty-five milligrams would be considered a moderate dose. It’s not a heroic dose necessarily, but it’s a psychoactive dose, for sure,” Kelmendi said. “The non-directive supportive psychotherapy is to be done after the dosing rather than during the dosing.”

The Many Potential Health Benefits of Psilocybin 

The Yale Program for Psychedelic Science supports this goal with several currently active studies on psilocybin. These include studies on Obsessive Compulsive Disorder (OCD), Major Depressive Disorder (MDD), cluster headaches, post-traumatic headaches, and migraines. Kelmendi is working on several of them.A 2022 report published by a working group under the direction of the Connecticut Department of Mental Health and Addiction Services, was clear about the potential of psilocybin in therapeutic medicine. 

Even people who don’t necessarily intend to gain benefits for mental health from psilocybin are still benefitting, a separate study suggests. A study published last September found that using psilocybin outside of a clinical setting was associated with mental health benefits including decreases in anxiety and depression. The research, which was published September in the journal Frontiers in Psychiatry, studied nearly 3,000 people who reported on their experience taking psilocybin mushrooms. 

To conduct the study, which is reportedly the largest study of psilocybin in a naturalistic (non-clinical) setting, researchers spent two years collecting data from 2,833 participants who planned to take psilocybin for purposes of “self-exploration.” Most participants were college-educated white men in the United States who had previous experience taking psychedelic drugs.

The study participants were asked to fill out five surveys as part of the research. The first survey was completed two weeks prior to the psilocybin experience, which usually consisted of ingesting dried mushrooms, and again the day before the planned psychedelic trip. The remaining surveys were taken one to three days after the experience, two to four weeks after and two to four months after taking the psilocybin. 

After analyzing the data from the surveys, researchers determined that participants reported long-lasting reductions in anxiety, depression, alcohol misuse, neuroticism and burnout. Additionally, the participants reported improvements in cognitive flexibility, emotion regulation, spiritual well-being and extraversion. The new research aims to add to the body of knowledge of what is known about the effects of psilocybin.

The post Yale Researchers To Study Psilocybin for PTSD, Mental Conditions first appeared on High Times.

The post Yale Researchers To Study Psilocybin for PTSD, Mental Conditions appeared first on Paradise Found.